Launching in Q1 2026, this cutting-edge technology from Quantum Life uses a single blood sample to analyse a patient’s entire genome, epigenetic markers, and clinical history.

Patients will receive a detailed report combining whole-genome sequencing which screens for inherited conditions, cancer predispositions, medication responses and polygenic risks for diseases such as Alzheimer’s and hypertension. With an epigenetic assessment that reveals the true biological age of individual organs and how lifestyle, stress and environment are accelerating or slowing aging, the programme aims to assist patients manage their health through tailored strategies rather than one-size-fits-all advice.

Dr Kenneth Tsang, Regional Chief Executive Officer of IHH Healthcare North Asia and Chief Executive Officer of Gleneagles Hospital Hong Kong, said, “At Gleneagles, we see innovation and technology as essential to shaping the future of healthcare. Over the years, we have been working with various health-tech partners to bring innovative solutions to our patients. This strategic collaboration with Quantum Life integrates AI and advanced multi-omics clinical analyses, which include genomics and epigenetics, into our services, enabling our patients to gain personalised health insights that support informed decisions and help prevent diseases before they develop. We believe this new service will set a new benchmark for personalised care.”

Starting at Gleneagles Medical Clinics in Central and Wong Chuk Hang, specially trained doctors will translate these insights into personalised prevention plans, spanning lifestyle changes to early medical interventions. 

This initiative from Gleneagles Hong Kong sets a new benchmark for precision medicine, helping our patients stay healthier, longer.